Femring is a brand name for an estrogen ring used for hormone replacement therapy (HRT) [1]. It is a vaginal ring that releases a steady dose of estradiol, a type of estrogen, directly into the bloodstream [2][3].
What is Femring used for?
Femring is prescribed to alleviate moderate to severe menopausal symptoms [3]. These symptoms can include hot flashes, vaginal dryness, and other issues related to estrogen deficiency [2][3]. It is also used to prevent bone loss in postmenopausal women [3].
How does the Femring work?
The vaginal ring is inserted into the vagina, where it slowly releases estradiol over a period of 90 days [2][3]. This direct delivery to the vaginal tissues and bloodstream bypasses the liver, which can be beneficial for some patients [2]. After 90 days, the ring is removed and can be replaced if continued treatment is needed [3].
What are the potential side effects of Femring?
Like other HRT, Femring carries potential risks and side effects. These can include an increased risk of endometrial cancer if used without a progestogen in women with a uterus, as well as risks of blood clots, stroke, and breast cancer, particularly with prolonged use [2][3]. Common side effects may include breast pain, headache, and vaginal discharge [3].
How does Femring compare to other HRT options?
Femring is a type of local estrogen therapy, differing from oral estrogen pills or transdermal patches that deliver estrogen systemically [2][3]. Its slow-release, localized delivery is a key characteristic. Other vaginal estrogen products exist, such as creams, tablets, and other rings, offering different delivery methods and durations of treatment [4].
When does the patent for Femring expire?
Information regarding specific patent expiry dates for Femring is available through specialized patent databases [1]. DrugPatentWatch.com tracks patent information for many pharmaceuticals, including those related to hormone therapy products [5].